| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 154 | 2025 | 1890 | 18.950 |
Why?
|
| Medication Adherence | 25 | 2020 | 401 | 5.150 |
Why?
|
| Anti-HIV Agents | 30 | 2025 | 314 | 4.860 |
Why?
|
| Patient Compliance | 24 | 2018 | 473 | 4.270 |
Why?
|
| Patient Acceptance of Health Care | 22 | 2018 | 422 | 3.800 |
Why?
|
| Antiretroviral Therapy, Highly Active | 28 | 2015 | 266 | 3.050 |
Why?
|
| Viral Load | 23 | 2020 | 384 | 3.010 |
Why?
|
| Mass Screening | 19 | 2022 | 784 | 2.820 |
Why?
|
| Health Services Accessibility | 15 | 2019 | 606 | 2.750 |
Why?
|
| Anti-Retroviral Agents | 12 | 2025 | 140 | 2.730 |
Why?
|
| Continuity of Patient Care | 9 | 2018 | 154 | 2.590 |
Why?
|
| AIDS Serodiagnosis | 9 | 2019 | 56 | 2.440 |
Why?
|
| Patient-Centered Care | 8 | 2020 | 225 | 2.390 |
Why?
|
| Physician-Patient Relations | 9 | 2018 | 426 | 2.220 |
Why?
|
| Trust | 7 | 2017 | 75 | 2.070 |
Why?
|
| Delivery of Health Care | 13 | 2020 | 606 | 2.000 |
Why?
|
| Adult | 119 | 2025 | 29398 | 2.000 |
Why?
|
| HIV | 9 | 2024 | 179 | 1.780 |
Why?
|
| Middle Aged | 103 | 2025 | 26461 | 1.770 |
Why?
|
| Health Knowledge, Attitudes, Practice | 15 | 2018 | 848 | 1.760 |
Why?
|
| Texas | 39 | 2025 | 3591 | 1.730 |
Why?
|
| Primary Health Care | 12 | 2019 | 772 | 1.660 |
Why?
|
| Male | 142 | 2025 | 61033 | 1.630 |
Why?
|
| Hospitalization | 9 | 2019 | 1756 | 1.600 |
Why?
|
| CD4 Lymphocyte Count | 22 | 2019 | 230 | 1.590 |
Why?
|
| HIV Seropositivity | 5 | 2012 | 119 | 1.540 |
Why?
|
| Health Promotion | 5 | 2017 | 392 | 1.490 |
Why?
|
| Patient Satisfaction | 4 | 2017 | 479 | 1.470 |
Why?
|
| Female | 129 | 2025 | 66307 | 1.470 |
Why?
|
| Young Adult | 47 | 2020 | 8979 | 1.460 |
Why?
|
| Humans | 185 | 2025 | 124409 | 1.410 |
Why?
|
| Ambulatory Care Facilities | 11 | 2022 | 227 | 1.290 |
Why?
|
| Cross-Sectional Studies | 22 | 2024 | 3427 | 1.270 |
Why?
|
| United States | 55 | 2024 | 10775 | 1.220 |
Why?
|
| Community Health Centers | 4 | 2014 | 39 | 1.220 |
Why?
|
| Sexual Behavior | 5 | 2020 | 247 | 1.210 |
Why?
|
| Physicians | 6 | 2022 | 579 | 1.200 |
Why?
|
| Anemia, Sickle Cell | 4 | 2013 | 340 | 1.200 |
Why?
|
| Risk-Taking | 3 | 2020 | 94 | 1.190 |
Why?
|
| Veterans | 15 | 2023 | 1752 | 1.160 |
Why?
|
| Social Support | 5 | 2020 | 348 | 1.150 |
Why?
|
| Ambulatory Care | 6 | 2015 | 380 | 1.140 |
Why?
|
| Child Health Services | 3 | 2013 | 88 | 1.100 |
Why?
|
| Healthcare Disparities | 5 | 2024 | 430 | 1.080 |
Why?
|
| Surveys and Questionnaires | 17 | 2025 | 3735 | 1.040 |
Why?
|
| Medicare | 5 | 2024 | 422 | 1.020 |
Why?
|
| Disease Transmission, Infectious | 2 | 2018 | 86 | 1.000 |
Why?
|
| Peer Group | 3 | 2018 | 119 | 0.990 |
Why?
|
| Hepatitis C | 11 | 2010 | 364 | 0.980 |
Why?
|
| Cohort Studies | 36 | 2023 | 4733 | 0.950 |
Why?
|
| Adolescent | 46 | 2020 | 19360 | 0.940 |
Why?
|
| Serologic Tests | 3 | 2020 | 118 | 0.940 |
Why?
|
| Homosexuality, Male | 7 | 2020 | 63 | 0.930 |
Why?
|
| Communication | 5 | 2022 | 516 | 0.920 |
Why?
|
| Drug Prescriptions | 2 | 2024 | 220 | 0.910 |
Why?
|
| Physicians, Primary Care | 2 | 2016 | 94 | 0.900 |
Why?
|
| Quality of Health Care | 3 | 2013 | 389 | 0.850 |
Why?
|
| Telemedicine | 4 | 2024 | 439 | 0.840 |
Why?
|
| HIV-1 | 7 | 2022 | 463 | 0.810 |
Why?
|
| Sexual and Gender Minorities | 2 | 2020 | 63 | 0.790 |
Why?
|
| Pre-Exposure Prophylaxis | 3 | 2019 | 35 | 0.770 |
Why?
|
| Appointments and Schedules | 5 | 2015 | 49 | 0.760 |
Why?
|
| Prospective Studies | 17 | 2023 | 6089 | 0.720 |
Why?
|
| Health Care Surveys | 7 | 2016 | 286 | 0.720 |
Why?
|
| Aged | 40 | 2024 | 19481 | 0.710 |
Why?
|
| Text Messaging | 2 | 2019 | 31 | 0.710 |
Why?
|
| Health Services Needs and Demand | 4 | 2019 | 174 | 0.710 |
Why?
|
| Practice Guidelines as Topic | 4 | 2018 | 1264 | 0.700 |
Why?
|
| Substance-Related Disorders | 4 | 2021 | 459 | 0.700 |
Why?
|
| Survivors | 2 | 2015 | 344 | 0.700 |
Why?
|
| Chronic Disease | 3 | 2015 | 1186 | 0.680 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2020 | 38 | 0.680 |
Why?
|
| Insurance, Health | 2 | 2018 | 138 | 0.650 |
Why?
|
| Patient Participation | 2 | 2019 | 222 | 0.640 |
Why?
|
| Soft Tissue Infections | 1 | 2020 | 84 | 0.640 |
Why?
|
| Early Medical Intervention | 2 | 2016 | 30 | 0.620 |
Why?
|
| Community-Acquired Infections | 2 | 2020 | 240 | 0.610 |
Why?
|
| Health Services | 2 | 2015 | 71 | 0.600 |
Why?
|
| Dementia | 1 | 2023 | 450 | 0.590 |
Why?
|
| Internal Medicine | 2 | 2023 | 149 | 0.590 |
Why?
|
| Attitude to Health | 5 | 2018 | 262 | 0.590 |
Why?
|
| Unsafe Sex | 1 | 2017 | 22 | 0.580 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2020 | 221 | 0.570 |
Why?
|
| Community Health Workers | 4 | 2015 | 67 | 0.570 |
Why?
|
| Office Visits | 2 | 2019 | 77 | 0.570 |
Why?
|
| Cognition | 1 | 2022 | 737 | 0.570 |
Why?
|
| Infectious Disease Transmission, Vertical | 4 | 2015 | 240 | 0.570 |
Why?
|
| Interviews as Topic | 6 | 2019 | 377 | 0.570 |
Why?
|
| Patient Selection | 3 | 2017 | 688 | 0.560 |
Why?
|
| Drug Monitoring | 2 | 2025 | 168 | 0.560 |
Why?
|
| Mentors | 3 | 2016 | 143 | 0.560 |
Why?
|
| Behavior Therapy | 5 | 2016 | 257 | 0.550 |
Why?
|
| Patient Outcome Assessment | 2 | 2022 | 93 | 0.550 |
Why?
|
| Hospitals, Pediatric | 2 | 2013 | 781 | 0.550 |
Why?
|
| Counseling | 1 | 2018 | 216 | 0.540 |
Why?
|
| Retrospective Studies | 40 | 2023 | 16232 | 0.530 |
Why?
|
| Program Evaluation | 6 | 2019 | 449 | 0.510 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 786 | 0.510 |
Why?
|
| Health Personnel | 3 | 2025 | 507 | 0.500 |
Why?
|
| Hospitals, Veterans | 3 | 2017 | 355 | 0.500 |
Why?
|
| Socioeconomic Factors | 7 | 2015 | 872 | 0.500 |
Why?
|
| Guideline Adherence | 2 | 2018 | 377 | 0.500 |
Why?
|
| Sickness Impact Profile | 1 | 2015 | 37 | 0.490 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2018 | 720 | 0.490 |
Why?
|
| Reverse Transcriptase Inhibitors | 3 | 2011 | 35 | 0.480 |
Why?
|
| Community Health Services | 3 | 2018 | 89 | 0.480 |
Why?
|
| Urban Population | 6 | 2023 | 226 | 0.470 |
Why?
|
| Health Education | 3 | 2015 | 225 | 0.460 |
Why?
|
| Communication Barriers | 1 | 2014 | 39 | 0.460 |
Why?
|
| Anxiety | 3 | 2021 | 967 | 0.450 |
Why?
|
| Veterans Health | 1 | 2016 | 174 | 0.450 |
Why?
|
| Psychometrics | 2 | 2015 | 678 | 0.450 |
Why?
|
| Emergency Service, Hospital | 6 | 2018 | 1088 | 0.450 |
Why?
|
| Marketing of Health Services | 1 | 2014 | 25 | 0.450 |
Why?
|
| Reminder Systems | 2 | 2011 | 60 | 0.440 |
Why?
|
| Role | 1 | 2013 | 26 | 0.440 |
Why?
|
| Qualitative Research | 7 | 2019 | 549 | 0.440 |
Why?
|
| Protease Inhibitors | 2 | 2015 | 94 | 0.430 |
Why?
|
| Inpatients | 3 | 2023 | 496 | 0.430 |
Why?
|
| Social Marketing | 1 | 2013 | 9 | 0.420 |
Why?
|
| Risk Factors | 18 | 2022 | 10150 | 0.410 |
Why?
|
| Depression | 6 | 2022 | 1248 | 0.410 |
Why?
|
| Patient Preference | 1 | 2014 | 119 | 0.410 |
Why?
|
| Public Health | 2 | 2016 | 260 | 0.400 |
Why?
|
| Hospitals, Urban | 2 | 2015 | 97 | 0.390 |
Why?
|
| Internship and Residency | 2 | 2023 | 1177 | 0.390 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2019 | 162 | 0.390 |
Why?
|
| Quality of Life | 4 | 2015 | 1954 | 0.380 |
Why?
|
| Multivariate Analysis | 9 | 2015 | 1417 | 0.380 |
Why?
|
| Syphilis, Cutaneous | 1 | 2011 | 4 | 0.380 |
Why?
|
| Hospitals, General | 1 | 2011 | 24 | 0.370 |
Why?
|
| Skin Ulcer | 1 | 2011 | 32 | 0.370 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 125 | 0.370 |
Why?
|
| Language | 1 | 2013 | 204 | 0.370 |
Why?
|
| Anus Neoplasms | 4 | 2015 | 38 | 0.370 |
Why?
|
| Sexually Transmitted Diseases, Viral | 1 | 2010 | 4 | 0.360 |
Why?
|
| Disabled Children | 1 | 2011 | 25 | 0.360 |
Why?
|
| Poverty | 3 | 2015 | 418 | 0.360 |
Why?
|
| Parent-Child Relations | 1 | 2013 | 248 | 0.360 |
Why?
|
| Smoking Cessation | 2 | 2024 | 197 | 0.360 |
Why?
|
| Lost to Follow-Up | 3 | 2022 | 32 | 0.360 |
Why?
|
| Attitude of Health Personnel | 4 | 2025 | 673 | 0.360 |
Why?
|
| Interpersonal Relations | 1 | 2012 | 229 | 0.350 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2010 | 9 | 0.350 |
Why?
|
| Syphilis | 1 | 2011 | 96 | 0.350 |
Why?
|
| Motivation | 1 | 2013 | 314 | 0.350 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2011 | 141 | 0.340 |
Why?
|
| Communications Media | 1 | 2010 | 4 | 0.340 |
Why?
|
| Pain Measurement | 4 | 2014 | 360 | 0.340 |
Why?
|
| Time Factors | 9 | 2018 | 6273 | 0.340 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2009 | 938 | 0.330 |
Why?
|
| Vascular Diseases | 1 | 2011 | 166 | 0.330 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2015 | 449 | 0.330 |
Why?
|
| Reproducibility of Results | 5 | 2021 | 2875 | 0.320 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2024 | 1099 | 0.320 |
Why?
|
| Itraconazole | 1 | 2009 | 24 | 0.320 |
Why?
|
| Self Administration | 2 | 2011 | 43 | 0.320 |
Why?
|
| Treatment Outcome | 14 | 2016 | 12289 | 0.320 |
Why?
|
| Sierra Leone | 4 | 2018 | 30 | 0.320 |
Why?
|
| Histoplasmosis | 1 | 2009 | 47 | 0.320 |
Why?
|
| Electronic Health Records | 4 | 2024 | 723 | 0.310 |
Why?
|
| Pilot Projects | 5 | 2024 | 1404 | 0.310 |
Why?
|
| Regression Analysis | 4 | 2015 | 775 | 0.300 |
Why?
|
| Emergency Medical Services | 1 | 2013 | 436 | 0.300 |
Why?
|
| Liver Neoplasms | 3 | 2009 | 1318 | 0.290 |
Why?
|
| Alcoholism | 2 | 2023 | 231 | 0.290 |
Why?
|
| Thyroid Neoplasms | 2 | 2007 | 198 | 0.290 |
Why?
|
| Sleep Wake Disorders | 3 | 2014 | 179 | 0.290 |
Why?
|
| Cholangiocarcinoma | 1 | 2009 | 107 | 0.290 |
Why?
|
| Bile Duct Neoplasms | 1 | 2009 | 110 | 0.290 |
Why?
|
| Self Efficacy | 3 | 2013 | 200 | 0.270 |
Why?
|
| Health Plan Implementation | 2 | 2018 | 42 | 0.260 |
Why?
|
| Patient Education as Topic | 4 | 2019 | 443 | 0.260 |
Why?
|
| Databases, Factual | 1 | 2011 | 1174 | 0.260 |
Why?
|
| Prevalence | 8 | 2015 | 2433 | 0.260 |
Why?
|
| Public Health Practice | 2 | 2016 | 21 | 0.250 |
Why?
|
| Self Report | 3 | 2021 | 522 | 0.250 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2007 | 224 | 0.250 |
Why?
|
| Prisoners | 4 | 2010 | 35 | 0.240 |
Why?
|
| Pancreatic Neoplasms | 2 | 2009 | 685 | 0.240 |
Why?
|
| Logistic Models | 4 | 2015 | 1804 | 0.240 |
Why?
|
| Internet | 1 | 2007 | 384 | 0.230 |
Why?
|
| Neuropsychological Tests | 3 | 2023 | 929 | 0.230 |
Why?
|
| Infant | 9 | 2015 | 12480 | 0.230 |
Why?
|
| Patient Care | 2 | 2016 | 100 | 0.220 |
Why?
|
| Pediatrics | 1 | 2013 | 1165 | 0.220 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2015 | 656 | 0.220 |
Why?
|
| Eosinophilia | 2 | 2014 | 101 | 0.210 |
Why?
|
| Teaching Rounds | 1 | 2023 | 28 | 0.210 |
Why?
|
| Cell Phone | 2 | 2014 | 30 | 0.210 |
Why?
|
| Child, Preschool | 7 | 2015 | 14086 | 0.210 |
Why?
|
| Mobile Applications | 1 | 2024 | 92 | 0.210 |
Why?
|
| Parents | 3 | 2015 | 1039 | 0.200 |
Why?
|
| Creativity | 1 | 2022 | 13 | 0.200 |
Why?
|
| Liver Cirrhosis | 3 | 2007 | 834 | 0.190 |
Why?
|
| Health Policy | 2 | 2014 | 212 | 0.190 |
Why?
|
| Executive Function | 1 | 2022 | 106 | 0.190 |
Why?
|
| Survival Analysis | 5 | 2009 | 1482 | 0.190 |
Why?
|
| HIV Antibodies | 2 | 2022 | 69 | 0.190 |
Why?
|
| Child | 9 | 2016 | 24528 | 0.190 |
Why?
|
| Culture | 2 | 2012 | 67 | 0.190 |
Why?
|
| Rural Population | 1 | 2023 | 257 | 0.180 |
Why?
|
| Staphylococcus aureus | 2 | 2020 | 459 | 0.180 |
Why?
|
| Longitudinal Studies | 4 | 2019 | 1333 | 0.180 |
Why?
|
| Pain | 2 | 2014 | 472 | 0.180 |
Why?
|
| Disabled Persons | 1 | 2022 | 102 | 0.180 |
Why?
|
| Trypanosoma cruzi | 1 | 2024 | 232 | 0.180 |
Why?
|
| Mentoring | 1 | 2022 | 75 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 1086 | 0.170 |
Why?
|
| Emigrants and Immigrants | 2 | 2013 | 145 | 0.170 |
Why?
|
| Housing | 1 | 2020 | 59 | 0.170 |
Why?
|
| Early Diagnosis | 2 | 2014 | 180 | 0.170 |
Why?
|
| Chagas Disease | 1 | 2024 | 290 | 0.170 |
Why?
|
| Prisons | 2 | 2010 | 11 | 0.170 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2003 | 378 | 0.170 |
Why?
|
| Social Stigma | 1 | 2020 | 74 | 0.160 |
Why?
|
| Risk Assessment | 5 | 2015 | 3382 | 0.160 |
Why?
|
| Incidence | 9 | 2015 | 3086 | 0.160 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 6471 | 0.160 |
Why?
|
| Memory Disorders | 1 | 2021 | 238 | 0.160 |
Why?
|
| Hyperaldosteronism | 1 | 2019 | 16 | 0.160 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 9 | 0.160 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2012 | 811 | 0.160 |
Why?
|
| House Calls | 1 | 2018 | 37 | 0.150 |
Why?
|
| Drug Therapy, Combination | 3 | 2011 | 1154 | 0.150 |
Why?
|
| Chicago | 1 | 2018 | 21 | 0.150 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 5107 | 0.150 |
Why?
|
| Patients | 1 | 2019 | 121 | 0.150 |
Why?
|
| Linear Models | 2 | 2013 | 671 | 0.150 |
Why?
|
| Case-Control Studies | 5 | 2018 | 3268 | 0.150 |
Why?
|
| HIV Core Protein p24 | 1 | 2018 | 12 | 0.150 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 339 | 0.150 |
Why?
|
| HIV Serosorting | 1 | 2017 | 1 | 0.150 |
Why?
|
| Intention | 3 | 2013 | 92 | 0.150 |
Why?
|
| Mental Health | 1 | 2021 | 346 | 0.140 |
Why?
|
| Health Communication | 1 | 2018 | 26 | 0.140 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 2031 | 0.140 |
Why?
|
| Condoms | 1 | 2017 | 49 | 0.140 |
Why?
|
| Minority Health | 1 | 2017 | 11 | 0.140 |
Why?
|
| Tuberculosis | 1 | 2003 | 519 | 0.140 |
Why?
|
| Waiting Lists | 1 | 2019 | 227 | 0.140 |
Why?
|
| Factor Analysis, Statistical | 2 | 2015 | 239 | 0.140 |
Why?
|
| Minority Groups | 2 | 2013 | 251 | 0.140 |
Why?
|
| Sexual Partners | 1 | 2017 | 87 | 0.140 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 198 | 0.140 |
Why?
|
| Medically Underserved Area | 1 | 2017 | 90 | 0.130 |
Why?
|
| Perception | 1 | 2018 | 221 | 0.130 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2019 | 197 | 0.130 |
Why?
|
| Antiviral Agents | 3 | 2010 | 746 | 0.130 |
Why?
|
| Risk | 2 | 2009 | 749 | 0.130 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 141 | 0.130 |
Why?
|
| Sex Factors | 3 | 2010 | 1267 | 0.130 |
Why?
|
| Self-Assessment | 1 | 2015 | 66 | 0.120 |
Why?
|
| Survival Rate | 3 | 2010 | 2020 | 0.120 |
Why?
|
| Liver Diseases | 3 | 2007 | 366 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 1598 | 0.120 |
Why?
|
| Cities | 1 | 2014 | 47 | 0.120 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2005 | 136 | 0.110 |
Why?
|
| Splints | 1 | 2013 | 10 | 0.110 |
Why?
|
| Hepacivirus | 3 | 2010 | 241 | 0.110 |
Why?
|
| Hepatitis C, Chronic | 2 | 2010 | 324 | 0.110 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2014 | 76 | 0.110 |
Why?
|
| Visual Analog Scale | 1 | 2013 | 7 | 0.110 |
Why?
|
| Professional-Patient Relations | 1 | 2014 | 84 | 0.110 |
Why?
|
| Neuralgia | 1 | 2013 | 45 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 870 | 0.110 |
Why?
|
| Patient Advocacy | 1 | 2013 | 61 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 2416 | 0.110 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2014 | 128 | 0.100 |
Why?
|
| Failure to Thrive | 1 | 2013 | 90 | 0.100 |
Why?
|
| Violence | 1 | 2013 | 116 | 0.100 |
Why?
|
| Centralized Hospital Services | 1 | 2012 | 5 | 0.100 |
Why?
|
| Emtricitabine | 1 | 2012 | 2 | 0.100 |
Why?
|
| Homosexuality | 2 | 2010 | 18 | 0.100 |
Why?
|
| Tenofovir | 1 | 2012 | 16 | 0.100 |
Why?
|
| Organophosphonates | 1 | 2012 | 19 | 0.100 |
Why?
|
| Benzoxazines | 1 | 2012 | 24 | 0.100 |
Why?
|
| Alkynes | 1 | 2012 | 26 | 0.100 |
Why?
|
| Pneumonia, Pneumococcal | 2 | 2009 | 82 | 0.100 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 458 | 0.100 |
Why?
|
| Cyclopropanes | 1 | 2012 | 68 | 0.100 |
Why?
|
| Deoxycytidine | 1 | 2012 | 76 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2015 | 368 | 0.100 |
Why?
|
| Spouses | 1 | 2012 | 66 | 0.100 |
Why?
|
| Health Surveys | 1 | 2013 | 244 | 0.100 |
Why?
|
| Disease Progression | 3 | 2019 | 2041 | 0.100 |
Why?
|
| Adenine | 1 | 2012 | 101 | 0.100 |
Why?
|
| Motivational Interviewing | 1 | 2012 | 46 | 0.090 |
Why?
|
| Stereotyping | 1 | 2011 | 19 | 0.090 |
Why?
|
| Child, Exceptional | 1 | 2011 | 3 | 0.090 |
Why?
|
| ROC Curve | 1 | 2013 | 562 | 0.090 |
Why?
|
| Video Recording | 1 | 2013 | 183 | 0.090 |
Why?
|
| Poisson Distribution | 1 | 2011 | 48 | 0.090 |
Why?
|
| Community-Institutional Relations | 1 | 2011 | 30 | 0.090 |
Why?
|
| Family Practice | 1 | 2011 | 90 | 0.090 |
Why?
|
| Rural Health | 1 | 2011 | 48 | 0.090 |
Why?
|
| Niacin | 1 | 2011 | 57 | 0.090 |
Why?
|
| Fenofibrate | 1 | 2011 | 58 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 511 | 0.090 |
Why?
|
| Sulfamethizole | 1 | 2010 | 1 | 0.090 |
Why?
|
| Trimethoprim | 1 | 2010 | 4 | 0.090 |
Why?
|
| Dapsone | 1 | 2010 | 5 | 0.090 |
Why?
|
| Genes, pol | 1 | 2010 | 10 | 0.090 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2010 | 15 | 0.090 |
Why?
|
| Adiponectin | 1 | 2011 | 109 | 0.090 |
Why?
|
| Costs and Cost Analysis | 1 | 2011 | 164 | 0.090 |
Why?
|
| Drug Resistance, Viral | 1 | 2010 | 44 | 0.090 |
Why?
|
| Safe Sex | 1 | 2010 | 16 | 0.090 |
Why?
|
| Anemia, Hemolytic | 1 | 2010 | 30 | 0.090 |
Why?
|
| Focus Groups | 1 | 2011 | 202 | 0.090 |
Why?
|
| Affect | 1 | 2011 | 159 | 0.090 |
Why?
|
| Life Expectancy | 1 | 2010 | 53 | 0.090 |
Why?
|
| Health Facilities | 1 | 2010 | 59 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2013 | 472 | 0.090 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 138 | 0.090 |
Why?
|
| Disability Evaluation | 1 | 2011 | 193 | 0.090 |
Why?
|
| Viremia | 1 | 2010 | 128 | 0.080 |
Why?
|
| Needs Assessment | 1 | 2011 | 176 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 1243 | 0.080 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 79 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2010 | 266 | 0.080 |
Why?
|
| Disease Management | 1 | 2013 | 519 | 0.080 |
Why?
|
| Hepatitis B | 2 | 2008 | 160 | 0.080 |
Why?
|
| Age Factors | 3 | 2011 | 2805 | 0.080 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2009 | 12 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 152 | 0.080 |
Why?
|
| Pregnancy | 5 | 2015 | 7167 | 0.080 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2009 | 28 | 0.080 |
Why?
|
| Haemophilus Infections | 1 | 2009 | 91 | 0.080 |
Why?
|
| Haemophilus influenzae | 1 | 2009 | 130 | 0.080 |
Why?
|
| Physician's Role | 1 | 2010 | 165 | 0.080 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2009 | 49 | 0.080 |
Why?
|
| Health Resources | 2 | 2014 | 115 | 0.080 |
Why?
|
| Research | 1 | 2010 | 263 | 0.080 |
Why?
|
| Informed Consent | 1 | 2011 | 336 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2009 | 253 | 0.080 |
Why?
|
| Neoplasms | 2 | 2015 | 2800 | 0.080 |
Why?
|
| Cause of Death | 2 | 2014 | 468 | 0.080 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 76 | 0.080 |
Why?
|
| Dyslipidemias | 1 | 2011 | 229 | 0.070 |
Why?
|
| Pediatric Obesity | 1 | 2013 | 387 | 0.070 |
Why?
|
| Malawi | 3 | 2015 | 398 | 0.070 |
Why?
|
| SEER Program | 1 | 2009 | 199 | 0.070 |
Why?
|
| Hyperglycemia | 1 | 2009 | 222 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2022 | 767 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2010 | 265 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2011 | 2896 | 0.070 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2007 | 44 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 507 | 0.070 |
Why?
|
| Cryoglobulinemia | 1 | 2007 | 10 | 0.070 |
Why?
|
| Odds Ratio | 4 | 2013 | 1246 | 0.070 |
Why?
|
| Social Class | 1 | 2008 | 191 | 0.070 |
Why?
|
| Neurocysticercosis | 1 | 2007 | 27 | 0.070 |
Why?
|
| International Classification of Diseases | 1 | 2007 | 90 | 0.070 |
Why?
|
| Metabolic Syndrome | 1 | 2010 | 330 | 0.070 |
Why?
|
| Infant, Newborn | 3 | 2022 | 8185 | 0.070 |
Why?
|
| Streptococcus pneumoniae | 1 | 2009 | 372 | 0.070 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2007 | 166 | 0.070 |
Why?
|
| Prejudice | 1 | 2006 | 38 | 0.070 |
Why?
|
| Acute Coronary Syndrome | 1 | 2009 | 205 | 0.070 |
Why?
|
| Papanicolaou Test | 1 | 2006 | 33 | 0.060 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2007 | 669 | 0.060 |
Why?
|
| Vaginal Smears | 1 | 2006 | 48 | 0.060 |
Why?
|
| Asthma | 1 | 2013 | 748 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 1320 | 0.060 |
Why?
|
| Pandemics | 2 | 2023 | 1102 | 0.060 |
Why?
|
| Urban Health Services | 1 | 2005 | 22 | 0.060 |
Why?
|
| Carcinoma, Papillary | 1 | 2006 | 77 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2013 | 826 | 0.060 |
Why?
|
| Medical Records | 1 | 2005 | 190 | 0.060 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2007 | 121 | 0.060 |
Why?
|
| Calreticulin | 1 | 2004 | 20 | 0.060 |
Why?
|
| San Francisco | 1 | 2004 | 17 | 0.060 |
Why?
|
| Uncompensated Care | 1 | 2004 | 10 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2005 | 342 | 0.060 |
Why?
|
| Smokers | 1 | 2024 | 39 | 0.060 |
Why?
|
| Osteomyelitis | 1 | 2007 | 205 | 0.060 |
Why?
|
| Liver Failure, Acute | 1 | 2005 | 89 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2005 | 174 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2006 | 283 | 0.050 |
Why?
|
| Telephone | 1 | 2023 | 110 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 723 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2003 | 403 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2003 | 77 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2006 | 288 | 0.050 |
Why?
|
| DNA, Bacterial | 1 | 2003 | 475 | 0.050 |
Why?
|
| Comorbidity | 2 | 2021 | 1514 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2004 | 382 | 0.050 |
Why?
|
| RNA, Viral | 3 | 2010 | 539 | 0.050 |
Why?
|
| Staphylococcal Infections | 1 | 2007 | 556 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2005 | 539 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2004 | 434 | 0.050 |
Why?
|
| Machine Learning | 1 | 2024 | 242 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2003 | 318 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2006 | 1021 | 0.050 |
Why?
|
| Feedback | 1 | 2022 | 162 | 0.050 |
Why?
|
| Lebanon | 1 | 2020 | 5 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 405 | 0.040 |
Why?
|
| Data Collection | 2 | 2013 | 383 | 0.040 |
Why?
|
| Proteomics | 1 | 2004 | 491 | 0.040 |
Why?
|
| Mental Recall | 1 | 2021 | 142 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2020 | 41 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2008 | 824 | 0.040 |
Why?
|
| Patient Navigation | 1 | 2020 | 25 | 0.040 |
Why?
|
| Pharmacists | 1 | 2020 | 84 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 29 | 0.040 |
Why?
|
| Smoking | 1 | 2005 | 1037 | 0.040 |
Why?
|
| Software | 1 | 2024 | 686 | 0.040 |
Why?
|
| Registries | 2 | 2019 | 1410 | 0.040 |
Why?
|
| Prognosis | 4 | 2012 | 4553 | 0.040 |
Why?
|
| Directly Observed Therapy | 1 | 2018 | 24 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2009 | 279 | 0.040 |
Why?
|
| Tablets | 1 | 2018 | 28 | 0.040 |
Why?
|
| Health Services Research | 1 | 2019 | 187 | 0.040 |
Why?
|
| Algorithms | 1 | 2024 | 1612 | 0.030 |
Why?
|
| Uganda | 1 | 2017 | 68 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 117 | 0.030 |
Why?
|
| Adrenal Glands | 1 | 1996 | 43 | 0.030 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1996 | 66 | 0.030 |
Why?
|
| Probability | 2 | 2007 | 323 | 0.030 |
Why?
|
| Adenoma | 1 | 1996 | 135 | 0.030 |
Why?
|
| District of Columbia | 1 | 2014 | 16 | 0.030 |
Why?
|
| Financial Support | 1 | 2014 | 8 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 2122 | 0.030 |
Why?
|
| Program Development | 1 | 2016 | 188 | 0.030 |
Why?
|
| Health Behavior | 1 | 2018 | 384 | 0.030 |
Why?
|
| Walk Test | 1 | 2014 | 24 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2007 | 2088 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2014 | 93 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2015 | 161 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 656 | 0.030 |
Why?
|
| Exanthema | 1 | 2014 | 68 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 1996 | 357 | 0.030 |
Why?
|
| Premedication | 1 | 2013 | 43 | 0.030 |
Why?
|
| Standard of Care | 1 | 2014 | 129 | 0.030 |
Why?
|
| Exercise Test | 1 | 2014 | 248 | 0.030 |
Why?
|
| Mortality | 1 | 2014 | 229 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2012 | 72 | 0.030 |
Why?
|
| Community Networks | 1 | 2012 | 33 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2013 | 186 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 305 | 0.020 |
Why?
|
| Sleep | 1 | 2013 | 343 | 0.020 |
Why?
|
| Mutation | 2 | 2019 | 5805 | 0.020 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2010 | 92 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2011 | 179 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2012 | 348 | 0.020 |
Why?
|
| Health Planning | 1 | 2009 | 15 | 0.020 |
Why?
|
| Alabama | 1 | 2009 | 46 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2009 | 53 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2010 | 215 | 0.020 |
Why?
|
| Triglycerides | 1 | 2011 | 565 | 0.020 |
Why?
|
| Life Style | 1 | 2011 | 410 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2009 | 196 | 0.020 |
Why?
|
| Anticholesteremic Agents | 1 | 2010 | 234 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1619 | 0.020 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2007 | 57 | 0.020 |
Why?
|
| Methicillin Resistance | 1 | 2007 | 118 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2006 | 29 | 0.020 |
Why?
|
| Rifampin | 1 | 2007 | 128 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 1017 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 2006 | 67 | 0.020 |
Why?
|
| Papillomaviridae | 1 | 2006 | 137 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2009 | 483 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2007 | 548 | 0.020 |
Why?
|
| Exercise | 1 | 2011 | 821 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2005 | 101 | 0.010 |
Why?
|
| Research Design | 1 | 2009 | 687 | 0.010 |
Why?
|
| Vancomycin | 1 | 2007 | 218 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2006 | 402 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2004 | 43 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2007 | 677 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 2552 | 0.010 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2006 | 168 | 0.010 |
Why?
|
| Glycosylation | 1 | 2004 | 119 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 1245 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 413 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 1684 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 709 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2004 | 291 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2004 | 412 | 0.010 |
Why?
|
| Drug Therapy | 1 | 2003 | 85 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2004 | 331 | 0.010 |
Why?
|
| Pancreatitis | 1 | 2004 | 130 | 0.010 |
Why?
|
| Liver | 1 | 2010 | 1761 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 1108 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2004 | 247 | 0.010 |
Why?
|
| Biomarkers | 1 | 2010 | 2980 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 1015 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 2699 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2004 | 911 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 3873 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 1695 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2004 | 998 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1996 | 290 | 0.010 |
Why?
|